Australia Viscosupplementation Market Size & Outlook
Australia viscosupplementation market, 2018-2030 (US$M)
Related Markets
Australia viscosupplementation market highlights
- The Australia viscosupplementation market generated a revenue of USD 52.1 million in 2023 and is expected to reach USD 115.5 million by 2030.
- The Australia market is expected to grow at a CAGR of 12% from 2024 to 2030.
- In terms of segment, three injection was the largest revenue generating product in 2023.
- Single Injection is the most lucrative product segment registering the fastest growth during the forecast period.
Viscosupplementation market data book summary
| Market revenue in 2023 | USD 52.1 million |
| Market revenue in 2030 | USD 115.5 million |
| Growth rate | 12% (CAGR from 2023 to 2030) |
| Largest segment | Three injection |
| Fastest growing segment | Single Injection |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single Injection, Three Injection, Five Injection |
| Key market players worldwide | DePuy Synthes, Sanofi SA, Smith & Nephew PLC, Anika Therapeutics Inc, Zimmer Biomet Holdings Inc, Ferring, Lifecore Biomedical Inc, LG Chem, Roche Holding AG |
Other key industry trends
- In terms of revenue, Australia accounted for 1.1% of the global viscosupplementation market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan viscosupplementation market is projected to lead the regional market in terms of revenue in 2030.
- Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 115.5 million by 2030.
Three injection was the largest segment with a revenue share of 43.19% in 2023. Horizon Databook has segmented the Australia viscosupplementation market based on single injection, three injection, five injection covering the revenue growth of each sub-segment from 2018 to 2030.
Osteoarthritis predominant condition and is the most common form of arthritis in Australia that leads to knee and hips replacement surgery. According to the Australian Bureau of Statistics (ABS), 2014–15 National Health Survey (NHS) about 2.1 million i.e., 9% of the total population in Australia have been reported suffering from this condition.
Osteoarthritis represented over half (59%) of all arthritic conditions in 2014 – 2015. Around 21% i.e., 1 out of 5 Australians, aged over 45 suffers from osteoarthritis. Among the population, aged 80 years and older the condition is more common, with around 35% of people in this age group reporting the condition. Osteoarthritis is also more common in females than males, affecting 10% of females compared to 6% of males.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viscosupplementation Market Scope
Viscosupplementation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia viscosupplementation market size, by product, 2018-2030 (US$M)
Australia Viscosupplementation Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
